Introduction
Human parainfluenza virus type 3 (PIV-3), a paramyxovirus, is a major cause of respiratory disease in infants and young children. Parainfluenza viruses can cause lower respiratory disease usually in the form of the croup syndrome and often cause bronchitis, bronchiolitis or pneumonia (Chanock & McIntosh, 1990) . Similar to infections with other paramyxoviruses such as respiratory syncytial virus (RSV), nearly all children have been infected with PIV-3 by age 3 to 5 (Clyde & Denny, 1983) . Reinfection of older children and adults is common (Bloom et al., 1961) . A safe and effective vaccine does not currently exist for control of PIV-3 infection.
PIV-3 encodes two major glycoproteins, the F (fusion) and HN (haemagglutinin-neuraminidase) glycoproteins which represent major vaccine targets. Vaccination with either purified F or HN glycoproteins prepared from either recombinant expression vectors (Spriggs et al., 1987; Coelingh et aI., 1989; Ray et al., 1989) or by purification from infected cells has only partially protected animals from PIV-3 challenge (Ambrose et al., 1991 ; Ray et al., 1988; Hall et al., 1991) . Development of an experimental subunit vaccine for complete prevention of PIV-3 replication is warranted.
Our previous work with an experimental subunit vaccine termed FG, which is a chimeric glycoprotein containing both the F and G glycoproteins of RSV, prepared in insect cells using a baculovirus vector system, showed complete protection against RSV challenge in cotton rats (Brideau et al., 1989; Wathen et al., 1991) . In the preceding paper (Lehman et al., 1993) , we describe the construction of a chimeric FHN glycoprotein consisting of a truncated form of the F glycoprotein linked to a truncated form of the HN glycoprotein of PIV-3, as well as secreted forms of the individual glycoproteins. We now report that FHN vaccination completely protects cotton rats from experimental PIV-3 challenge and that vaccination with the FHN glycoprotein is superior to vaccination with either the F or HN glycoproteins alone or mixtures of both F and HN proteins. In addition we report that FHN vaccination results in induction of serum ELISA-positive and neutralizing (anti-PIV-3) antibodies in rats, and in induction of proliferative responses to PIV-3 glycoprotein antigens in cultures of lymph node cells taken from FHN-immunized mice.
vector under control of the polyhedrin promotor and were purified by immunoaffinity chromatography (Lehman et al., 1993) .
Vaccinations. Preparations of glycoproteins adsorbed to aluminium
hydroxide (alhydrogel from Superfos) were administered to rats intramuscularly (i.m.) at dosage levels indicated in each table. The actual amount of alhydrogel administered was 200 ~tg per dose. Two vaccinations were given 3 weeks apart. Ten days after the second vaccination, sera were prepared for antibody determinations. In some experiments, rats received mixtures of F and HN glycoproteins formulated in alhydrogel. A mixture of unit, five-and 10-fold amounts of F and HN glycoproteins contained (65 ng and 50 ng), (325 ng and 250 ng), and (650 ng and 500 rig), respectively. These mixtures were prepared in this way to adjust for mass differences between the F and HN glycoproteins and allow administration of equimolar amounts of the two proteins.
Proliferation assays. Mice were immunized in footpads with individual glycoproteins prepared in complete Freund's adjuvant (Gibco). At 14 days popliteal lymph node cells from immunized donor mice were collected as described (Brideau & Wathen, 1991) and cultured in the presence of various amounts of individual glycoproteins for 3 days. Approximately 1 laCi of tritiated thyrnidine (ICN) was added to cultures during the final 14 h of incubation, wells were harvested onto filter pads using a cell harvester (Skatron) and radioactivity was determined using scintillation counting as described (Brideau & Wolcott, 1987) .
Seroanalysis. Sera were assayed by ELISA for IgG antibody directed against either PIV-3-infected cell lysates or individual glycoproteins. Lysates and individual glycoproteins were preadsorbed to microtitre plates prior to assay. The assay was performed as previously described (Brideau et al., 1989) . ELISA titres were expressed as the reciprocal of the dilution of sera giving 50 % of the maximum binding activity. Neutralizing antibody titres were measured for individual sera against PIV-3-infected HEp-2 cell cultures as previously described (Brideau et al., 1989) and were expressed as the reciprocal of the highest dilution that reduced viral c.p.e, by 50 % relative to non-neutralized controls.
Absorptions. Dilutions of sera taken from FHN protein-vaccinated rats were reacted with saturating amounts (20 ~tg per reaction) of individual glycoproteins overnight at 4 °C. Residual binding activity of anti-FHN sera was assayed against PIV-3-infected cell lysates and against FHN antigen by ELISA. The percent residual binding activity was derived from titration curves for each sample and was recorded as a percentage of control (mock-absorbed) activity.
PIV-3 challenge and lung harvest. In vaccination studies cotton rats were challenged with approximately 2 x 106 p.f.u, of PIV-3 intranasally at 2 weeks after the second vaccination. Four days after virus challenge, lung tissues were removed and processed as 10 % (w/v) homogenates in cell culture medium. Virus titres were determined on HEp-2 cells and expressed as the average p.f.u, per gram of lung tissue for infected animals in each treatment group. The level of detectable virus was 1017/g of lung tissue.
Statistical analysis. Student's t-test determinations were completed as indicated in each table for groups with more than one infected animal and P values are shown. using a baculovirus vector system (see preceding paper, Lehman et al., 1993) . Each of the individual glycoproteins (F and HN) and the chimeric FHN glycoprotein lack an appropriate membrane anchor sequence and are shown in Fig. 1 . Protein material was purified to > 95 % homogeneity following affinity chromatography and was used to vaccinate cotton rats for evaluation of both antibody and protective immune responses and to also immunize mice for measurement of lymphocytic proliferative responses.
Antibody response of animals to individual PIV-3 glycoproteins
Cotton rats received two vaccinations with either F, HN or the chimeric FHN glycoprotein. Serum IgG responses to individual glycoproteins or to PIV-3-infected target cells were measured in these animals ( Table 1) . Each of the individual glycoproteins administered induced serum antibody reactive with PIV-3-infected target cells. Sera from F protein-vaccinated animals also recognized F and FHN antigens and sera from HN protein-vaccinated animals recognized HN-and FHN-specific antigens. Sera from FHN protein-vaccinated animals recognized F, HN and FHN antigens. For each particular glycoprotein used to vaccinate animals (F, HN or FHN), increasing the amount of antigen generally resulted in an increase in the amount of serum IgG antibody as measured by ELISA.
To show additional evidence that FHN glycoproteinvaccinated animals recognized both F-and HN-specific antigens, and thus reflect responsiveness to both the F and HN portions of the FHN chimeric glycoprotein, samples of anti-FHN sera from animals were preabsorbed with saturating amounts of the individual glycoproteins (F, HN and FHN) and assayed back against PIV-3-infected target cells (native F and HN), or back against FHN (recombinant) antigen (Table 2) . Preabsorption with mock antigen did not reduce the titre of the anti-FHN sera bound to PIV-3-infected target cells or to FHN antigen, and this group was normalized to 100%. Preabsorption with FHN antigen did reduce the residual binding of anti-FHN sera by >90 % as expected. Preabsorption with either F or HN partially reduced the binding capacity of the anti-FHN sera against both PIV-3-infected target cells and FHN antigen.
Results
The individual glycoproteins of PIV-3 including the F and HN glycrproteins and the chimeric FHN glycoprotein were expressed in insect cells in a secreted form vitro (Fig. 2) . Popliteal lymph node cells were harvested from groups of mice and were cultured in the presence of individual antigens (F, HN and FHN) . Recognition of the individual glycoproteins was measured via uptake of tritiated thymidine by primed cells. Lymph node cells from FHN protein-immunized mice responded to F, HN and FHN proteins significantly above the response to medium (mock antigen). In addition, lymph node cells taken from F and HN protein-immunized mice responded significantly to the FHN antigen.
Proliferative response to individual PIV-3 glycoproteins

Protection against PIV-3 challenge
Cotton rats which received two vaccinations with various glycoproteins were challenged with PIV-3 ( Table 3 ). The level of anti-PIV-3 neutralizing antibodies was also measured for each animal group. In this study, each of the alhydrogel-vaccinated controls was infected with PIV-3. Significant levels of neutralizing antibody (> 40) were not found for F protein-vaccinated animals and these animals were only partially protected from PIV-3 * Sera from five cotton rats which had been vaccinated twice (days 1 and 21) with the FHN glycoprotein were titrated by ELISA and used in absorption analysis. FHN glycoprotein was >~ 95 % pure and was formulated with 200 tag/dose of alhydrogel.
t Twenty lag of individual glycoprotein was incubated with a 200-fold dilution of anti-FHN sera (pool) for 14 h at 4 °C.
Residual ELISA binding activity of absorbed anti-FHN sera was measured against both PIV-3-infected target cells and against the FHN glycoprotein. The titre for each sample was compared to culture medium-absorbed serum which was normalized to 100%. animals and vaccination with doses of 10 and 50 ng of FHN resulted in statistically significant reductions in the level of PIV-3 found in lung tissue. Neutralizing antibodies against PIV-3 were found in sera of HN and FHN protein-vaccinated animals and were found to increase as the dosage of glycoprotein increased. Those ) and were bled 10 days following the second vaccination. Animals were challenged intranasally with PIV-3 14 days after the second vaccination• Four days after challenge, the lungs were removed, prepared as a 10 % homogenate and titrated for virus. Data from two experiments.
t Each of the glycoproteins was > 95 % pure and was formulated with 200 lag/dose of alhydrogel.
Neutralizing titre expressed as the reciprocal of the dilution that reduced viral c.p.e, by 50 % relative to non-neutralized controls (alhydrogel) against PIV-3.
§ Number of animals with detectable virus (> 1017) in their lungs at removal. 11 Average lung titre per gram tissue of infected animals in each group. The S.B.M. is indicated for groups with more than one infected animal.
¶ P value comparisons of each group to alhydrogel-infected animals. Ns, Not significant. ¶ P value comparisons of each group to alhydrogel-infected animals. Ns, Not significant.
groups of animals which were completely protected against PIV-3 (HN at 2500 rig, FHN at 200 and 800 ng), also had the highest levels of neutralizing antibodies (>100).
Efficacy of FHN glycoprotein compared to mixtures of F and HN glycoproteins
A comparison was made of the relative protective effect of FHN glycoprotein vaccination in cotton rats to that of mixtures of F and HN glycoproteins. Table 4 compares the immunogenicity of equivalent amounts of the individual F, HN or FHN glycoproteins to that of a mixture of unit, five-and 10-fold to that of a mixture of amounts (equimolar relative to the FHN glycoprotein) of F and HN glycoproteins respectively. In this study each of the alhydrogel controls was infected with PIV-3. On an equivalent weight basis using 100 ng/dose of glycoprotein, only the FHN glycoprotein was completely protective, whereas HN was partially protective, and F was not significantly protective against PIV-3 infection. Each of the individual glycoproteins (F, HN or FHN) induced serum IgG antibody reactive with PIV-3-infected target cells. Mixtures of unit, five-and 10-fold amounts of F and HN were not completely protective against PIV-3 challenge. However each specific mixture tested significantly reduced the amount of PIV-3 recovered from lung tissue and induced levels of neutralizing antibody similar to those seen with the equivalent dose of HN glycoprotein alone. A dose of 100 ng of FHN was completely protective and resulted in induction of the highest amount of neutralizing antibody (140) against PIV-3.
Discussion
We have compared the efficacy of FHN, a chimeric glycoprotein which contains the immunogenic regions of the F and HN glycoproteins of human PIV-3, to that of the individual F and HN glycoproteins using a model of experimental human PIV-3 infection in cotton rats. Each of the glycoproteins (F, HN and FHN) was expressed in insect cells using a baculovirus vector. Vaccination with the FHN chimeric glycoprotein was superior to vaccination with the F or HN glycoproteins, and resulted in complete protection of cotton rats from PIV-3 challenge at dosage levels of 100 ng or greater. A dose of as little as 10 ng of FHN glycoprotein significantly reduced the titre of PIV-3 in lung tissue. We also report that vaccination with the HN glycoprotein resulted in complete protection of cotton rats at dosage levels of 2500 ng. Vaccination with as much as 4000 ng of the F glycoprotein was not completely protective. Neutralizing antibody was detected in sera of FHN and HN proteinvaccinated animals but not in sera of F proteinvaccinated rats. The highest titres of neutralizing antibody against PIV-3 were found for those groups of animals which were completely protected from PIV-3 challenge. Analysis of IgG reactivity in sera from FHN proteinvaccinated animals showed that both native and recombinant forms of the F and HN glycoproteins were being recognized. In addition, preabsorption of anti-FHN sera with F or HN antigen partially abolished anti-FHN reactivity suggesting immune recognition of regions of both the F and HN glycoproteins by the animals vaccinated with FHN. Sera from FHN proteinvaccinated cotton rats also immunoprecipitated both F and HN glycoproteins from PIV-3-infected HEp-2 cells (data not shown). Furthermore, analysis of proliferative responses of FHN protein-immunized inbred mice showed that lymph node cells taken from FHN proteinimmunized donor mice responded to both the F and HN glycoprotein antigens in vitro. Cells taken from F or HN protein-immunized donor mice also responded to FHN glycoprotein antigen in vitro. These results suggest T cell recognition of epitopes on the FHN protein which are expressed on the F and HN portions of FHN. We had previously shown specific T cell recognition of the FG chimeric glycoprotein of RSV, which was also expressed in insect cells using a baculovirus vector (Brideau & Wathen, 1991) .
We also compared the response to PIV-3 challenge of FHN protein-vaccinated cotton rats to that of animals which were vaccinated with mixtures of both the F and HN glycoproteins. FHN vaccination was superior to mixtures of F and HN at unit five-and 10-fold doses of FHN (on an equivalent weight basis), conferring complete protection against PIV-3 challenge. Although none of the mixtures of F and HN proteins were completely protective, vaccination with each of the mixtures resulted in a significant reduction in the amount of PIV-3 recovered from lung tissue. Others (Ambrose et al., 1991 ; Hall et al., 1991) have shown that mixtures of the F and HN glycoproteins were also not completely protective against experimental PIV-3 infection in cotton rats. Our data suggest that simply exposing the immune system to mixtures of both the F and HN glycoproteins was no more effective than vaccination with HN protein alone. However, vaccination with the chimeric FHN protein did induce a greater protective immune response than did mixtures of the two glycoproteins, indicating that fusion of the F and HN proteins into a single glycoprotein enhanced the immunogenicity of one or both portions of the glycoprotein. A similar phenomenon was observed with an RSV chimeric FG glycoprotein where the immunogenicity of the F portion of the chimera was greater than observed with the F protein alone (N. L. Oien, unpublished results). Although the mechanism that confers enhanced immunogenicity upon the chimeric FHN protein compared to the individual glycoproteins is not understood, several possibilities do exist. The FHN glycoprotein may be folded into a more correct conformation, eliciting antibodies that recognize virus to a greater degree than the individual secreted glycoproteins. A conformational change which resulted in the correct cleavage into its subunits was observed for the RSV chimeric FG glycoprotein (N. L. Oien, unpublished results).
Taken together, these results showing recognition of epitopes on the F and HN glycoprotein in antibody reactions (Tables 1 and 2 ) and in proliferative responses (Fig. 2) suggest FHN-vaccinated animals are responding to both the F and HN portions. In our previous work using the FG chimeric glycoprotein for control of RSV infection, we had shown that the majority of the anti-FG antibody response was to the F portion of FG (Brideau et al., 1989) . Host response to more than one major viral glycoprotein target may be needed to control paramyxovirus infections effectively. The exact role of cellmediated and antibody-mediated immunity to PIV-3 remains poorly understood. We have shown here, experimentally, that FHN-vaccinated animals responded with both antibody and cellular immune reactivity to PIV-3 antigens. It is likely that these types of responses need to be elicited by any subunit candidate vaccine for the effective control of human paramyxovirus infection.
